

# Kwang Kon Koh

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2032685/kwang-kon-koh-publications-by-year.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

70  
papers

3,505  
citations

31  
h-index

59  
g-index

74  
ext. papers

3,824  
ext. citations

7  
avg, IF

4.86  
L-index

#	Paper	IF	Citations
70	Which biomarker to use, when to start, and how to improve adherence for reducing atherosclerotic cardiovascular disease risk?. <i>European Heart Journal</i> , <b>2021</b> , 42, 1808	9.5	1
69	Cardiovascular effects of omega-3 fatty acids: Hope or hype?. <i>Atherosclerosis</i> , <b>2021</b> , 322, 15-23	3.1	8
68	New Trends in Dyslipidemia Treatment. <i>Circulation Journal</i> , <b>2021</b> , 85, 759-768	2.9	4
67	Left Atrial Thrombus and Multiple Infarcts. <i>Cardiometabolic Syndrome Journal</i> , <b>2021</b> , 1, 114		
66	Metabolic Syndrome Fact Sheet 2021: Executive Report. <i>Cardiometabolic Syndrome Journal</i> , <b>2021</b> , 1, 125		5
65	Lipoprotein(a) and Cardiovascular Diseases - Revisited. <i>Circulation Journal</i> , <b>2020</b> , 84, 867-874	2.9	9
64	Impact of Longitudinal Changes in Metabolic Syndrome Status over 2 Years on 10-Year Incident Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , <b>2019</b> , 43, 530-538	5	14
63	Letter by Koh Regarding Article, "Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)". <i>Circulation</i> , <b>2019</b> , 139, 416-417	16.7	
62	Letter by Koh Regarding Article, "Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)". <i>Circulation</i> , <b>2019</b> , 139, 100-101	16.7	
61	Letter by Koh Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". <i>Circulation</i> , <b>2018</b> , 137, 2660-2661	16.7	
60	Letter by Koh Regarding Article, "PCSK9 Variants, Low-Density Lipoprotein Cholesterol, and Neurocognitive Impairment: Reasons for Geographic and Racial Differences in Stroke Study (REGARDS)". <i>Circulation</i> , <b>2018</b> , 138, 1283-1284	16.7	
59	Letter by Koh Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease". <i>Circulation</i> , <b>2018</b> , 138, 846-847	16.7	
58	Letter by Koh Regarding Article, "Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". <i>Circulation</i> , <b>2018</b> , 138, 1914-1915	16.7	
57	Letter by Koh Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up". <i>Circulation</i> , <b>2018</b> , 137, 2417-2419	16.7	
56	Letter by Koh Regarding Articles, "Predicting the 10-Year Risks of Atherosclerotic Cardiovascular Disease in Chinese Population: The China-PAR Project (Prediction for ASCVD Risk in China)" and "Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Community-Based Population". <i>Circulation</i> , <b>2017</b> , 135, 818-819	16.7	1
55	Letter by Koh Regarding Article, "Dipeptidyl Peptidase-4 Induces Aortic Valve Calcification by Inhibiting Insulin-Like Growth Factor-1 Signaling in Valvular Interstitial Cells". <i>Circulation</i> , <b>2017</b> , 136, 1668-1669 <sup>1</sup>	16.7	1
54	The role of insulin resistance and metabolic risk factors on culprit coronary plaque. <i>International Journal of Cardiology</i> , <b>2015</b> , 190, 56-62	3.2	6

53	How to balance cardiorenometabolic benefits and risks of statins. <i>Atherosclerosis</i> , <b>2014</b> , 235, 644-8	3.1	19
52	Rosuvastatin treatment improves arterial stiffness with lowering blood pressure in healthy hypercholesterolemic patients. <i>International Journal of Cardiology</i> , <b>2014</b> , 176, 1284-7	3.2	11
51	Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients. <i>International Journal of Cardiology</i> , <b>2013</b> , 166, 509-15	3.2	44
50	Repeated Aborted Sudden Cardiac Death with Long QT Syndrome in a Patient with Anomalous Origin of the Right Coronary Artery from the Left Coronary Cusp. <i>Korean Circulation Journal</i> , <b>2013</b> , 43, 830-3	2.2	2
49	Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia. <i>Atherosclerosis</i> , <b>2012</b> , 220, 537-44	3.1	41
48	Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension. <i>International Journal of Cardiology</i> , <b>2011</b> , 146, 319-25	3.2	23
47	Differential metabolic effects of distinct statins. <i>Atherosclerosis</i> , <b>2011</b> , 215, 1-8	3.1	103
46	Increasing prevalence of metabolic syndrome in Korea: the Korean National Health and Nutrition Examination Survey for 1998-2007. <i>Diabetes Care</i> , <b>2011</b> , 34, 1323-8	14.6	459
45	Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 55, 1209-1216	15.1	165
44	Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. <i>International Journal of Cardiology</i> , <b>2010</b> , 140, 73-81	3.2	57
43	Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction. <i>Atherosclerosis</i> , <b>2010</b> , 209, 307-13	3.1	45
42	Amlodipine improves endothelial function and metabolic parameters in patients with hypertension. <i>International Journal of Cardiology</i> , <b>2009</b> , 133, 23-31	3.2	31
41	Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. <i>Atherosclerosis</i> , <b>2009</b> , 204, 483-90	3.1	93
40	Does reversal of oxidative stress and inflammation provide vascular protection?. <i>Cardiovascular Research</i> , <b>2009</b> , 81, 649-59	9.9	62
39	Clinical Significance of Left Ventricular Torsional Parameters during Supine Bicycle Cardiopulmonary Exercise Echocardiography. <i>Journal of Cardiovascular Imaging</i> , <b>2009</b> , 17, 2	0	
38	Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates. <i>International Journal of Cardiology</i> , <b>2008</b> , 124, 149-59	3.2	34
37	Are statins effective for simultaneously treating dyslipidemias and hypertension?. <i>Atherosclerosis</i> , <b>2008</b> , 196, 1-8	3.1	30
36	Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. <i>Diabetes Care</i> , <b>2008</b> , 31, 776-82	14.6	94

35	Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients. <i>European Heart Journal</i> , <b>2007</b> , 28, 1440-7	9.5	41
34	Efonidipine simultaneously improves blood pressure, endothelial function, and metabolic parameters in nondiabetic patients with hypertension. <i>Diabetes Care</i> , <b>2007</b> , 30, 1605-7	14.6	37
33	Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1+2 in patients with type 2 diabetes. <i>Atherosclerosis</i> , <b>2007</b> , 194, 230-7	7.1	20
32	Controversies regarding hormone therapy: Insights from inflammation and hemostasis. <i>Cardiovascular Research</i> , <b>2006</b> , 70, 22-30	9.9	27
31	Images in cardiovascular medicine. Neovascularization from coronary artery leaking to fungus ball in the lung. <i>Circulation</i> , <b>2006</b> , 114, e551-2	16.7	1
30	Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients. <i>Diabetes Care</i> , <b>2006</b> , 29, 195-201	14.6	54
29	Anti-inflammatory and metabolic effects of candesartan in hypertensive patients. <i>International Journal of Cardiology</i> , <b>2006</b> , 108, 96-100	3.2	89
28	Vascular and metabolic effects of candesartan: insights from therapeutic interventions. <i>Journal of Hypertension</i> , <b>2006</b> , 24, S31-8	1.9	18
27	Significant differential effects of lower doses of hormone therapy or tibolone on markers of cardiovascular disease in post-menopausal women: a randomized, double-blind, crossover study. <i>European Heart Journal</i> , <b>2005</b> , 26, 1362-8	9.5	28
26	Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. <i>Journal of the American College of Cardiology</i> , <b>2005</b> , 45, 1649-53	15.1	179
25	Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. <i>Journal of the American College of Cardiology</i> , <b>2005</b> , 46, 1978-85	15.1	287
24	Efficacy of Thrombosuction using the Export Aspiration Catheter before Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction. <i>Korean Circulation Journal</i> , <b>2005</b> , 35, 172	2.2	2
23	Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. <i>Hypertension</i> , <b>2005</b> , 45, 1088-93	8.5	126
22	Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. <i>Diabetes Care</i> , <b>2005</b> , 28, 1419-24	14.6	159
21	Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. <i>Circulation</i> , <b>2004</b> , 110, 3687-92	16.7	243
20	Simvastatin combined with ramipril treatment in hypercholesterolemic patients. <i>Hypertension</i> , <b>2004</b> , 44, 180-5	8.5	41
19	Should progestins be blamed for the failure of hormone replacement therapy to reduce cardiovascular events in randomized controlled trials?. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2004</b> , 24, 1171-9	9.4	41
18	Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension. <i>American Journal of Cardiology</i> , <b>2004</b> , 93, 1432-5, A10	3	55

17	Vascular effects of diet and statin in hypercholesterolemic patients. <i>International Journal of Cardiology</i> , <b>2004</b> , 95, 185-91	3.2	40
16	Comparative effects of statin and fibrate on nitric oxide bioactivity and matrix metalloproteinase in hyperlipidemia. <i>International Journal of Cardiology</i> , <b>2004</b> , 97, 239-44	3.2	28
15	Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis. <i>Atherosclerosis</i> , <b>2004</b> , 174, 379-83	3.1	61
14	Vascular effects of simvastatin combined with ramipril in hypercholesterolemic patients with coronary artery disease, compared with simvastatin alone: a randomized, double-blind, placebo-controlled, crossover study. <i>Atherosclerosis</i> , <b>2004</b> , 177, 147-53	3.1	12
13	Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled study. <i>Atherosclerosis</i> , <b>2004</b> , 177, 155-60	3.1	56
12	Evaluation of Sympathetic Reinnervation Using 123I-MIBG Scintigraphy in Cardiac Transplants. <i>Sunhwanŭgi</i> , <b>2003</b> , 33, 909		
11	Effects of Simvastatin Alone or Combined With Ramipril on Nitric Oxide Bioactivity and Inflammation Markers in Hypercholesterolemic Patients. <i>Sunhwanŭgi</i> , <b>2003</b> , 33, 1053		7
10	Comparative effects of diet and simvastatin on markers of thrombogenicity in patients with coronary artery disease. <i>American Journal of Cardiology</i> , <b>2003</b> , 91, 1231-4	3	6
9	Vascular effects of step I diet in hypercholesterolemic patients with coronary artery disease. <i>American Journal of Cardiology</i> , <b>2003</b> , 92, 708-10	3	10
8	Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. <i>Journal of the American College of Cardiology</i> , <b>2003</b> , 42, 905-10	15.1	197
7	Can a healthy endothelium influence the cardiovascular effects of hormone replacement therapy?. <i>International Journal of Cardiology</i> , <b>2003</b> , 87, 1-8	3.2	25
6	Significant differential effects of hormone therapy or tibolone on markers of cardiovascular disease in postmenopausal women: a randomized, double-blind, placebo-controlled, crossover study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2003</b> , 23, 1889-94	9.4	44
5	Effects of hormone replacement therapy on coagulation and fibrinolysis in postmenopausal women. <i>International Journal of Hematology</i> , <b>2002</b> , 76 Suppl 2, 44-6	2.3	12
4	Comparative effects of diet and statin on NO bioactivity and matrix metalloproteinases in hypercholesterolemic patients with coronary artery disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2002</b> , 22, e19-23	9.4	80
3	Effects of continuous combined hormone replacement therapy on inflammation in hypertensive and/or overweight postmenopausal women. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2002</b> , 22, 1459-64	9.4	28
2	Effects of estrogen on the vascular wall: vasomotor function and inflammation. <i>Cardiovascular Research</i> , <b>2002</b> , 55, 714-26	9.9	77
1	Long-term Outcomes of Primary Stenting in Acute Myocardial Infarction. <i>Sunhwanŭgi</i> , <b>2001</b> , 31, 742		